Novus Nutrition Brands LLC (St. Louis), a subsidiary of Novus International Inc., has agreed to lease a dedicated R&D lab space for its Stratum Nutrition and Arenus divisions.
Novus Nutrition Brands LLC (St. Louis), a subsidiary of Novus International Inc., has agreed to lease a dedicated R&D lab space for its Stratum Nutrition and Arenus divisions.
Stratum Nutrition focuses on branded specialty and functional ingredients for foods, beverages, and dietary supplements, while Arenus produces supplements for the equine and companion animal market.
The new, separate space is located at Bio-Research & Development Growth (BRDG) Park at the Danforth Plant Science Center, located near Novus’s headquarters in St. Louis. The building features wet labs and office space. For Stratum, it will provide lab tools for conducting basic research and applications testing in food and dietary supplements.
“The presence of these labs within the BRDG Park allows us to strengthen our relationship with Danforth Plant Science Center and other companies that have a common interest in addressing the world food challenges,” said Ibrahim Abou-Nemeh, director of R&D, product discovery, for Novus International.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.